» Download Public Reports
About 600 reports
- Country report
- April 2013
- 10 pages
January 2013
... Archive a72 media contacts a71 campaigns a71 print this page a71 email to a friend a71 link to this page a71 save as pdf news & campaigning > media centre > latest news & developments > lung cancer ...
April 2013
... Related chronic diseases. Hurst et al,41 found that the euroqol offers good reliability and validity for the assessment of quality of life in rheumatoid arthritis patients. However, wolfe and hawley42 found ...
March 2013
... For patients in spain. Epidermolysis bullosa , scl Scleroderma, cf cystic fibrosis, hemo Prader-willi syndrome, xfr Fragile x syndrome. Direct non ...
December 2012
... In depression scores after 1 year. Systematic review: anglin 2013. Twice as likely to be depressed if vitamin d low. Mental health umhau, 2013: of 500 suicides in us military service members : those ...
November 2012
... mental disorder increases health risk behaviour Smoking as an example Largest single preventable cause of death 42% Of adult tobacco consumption in england is by those with mental disorder (mc ...
December 2012
... A, li y, tong y, zheng h, wu w, wei c. Abstract it has been previously demonstrated that vitamin d acts as a prognostic indicator of gastric cancer and may be correlated with the incidence risk ...
April 2013
... Official figures show. Circulatory conditions like heart disease remain the most common cause of death, contributing to a third of the deaths registered. But over the decade, mortality from ...
February 2013
... Of the global fight against infectious diseases Kofi annan, nobel peace prize laureate and former secretary- general of the united nations. Keppel street building and gardens. Anne koerber / lshtm 11keppel ...
April 2013
... Nonsurgical polyp removal complete colonic examination age 35 years or older; no history of colorectal cancer, inflammatory bowel disease, or large bowel resection; satisfactory completion of a food ...
» Purchase Premium Reports
(From $ 250 - $ 6 995)
About 400 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
